Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition Pharmaceutical TechnologyData from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk's CagriSema in adults with obesity.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk’s CagriSema in adults with obesity. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Clock starts ticking on UK’s single patient record planNext: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B Related Stories Clinical Data ECO 2026: tirzepatide shows potential for T1D treatment pharminent May 15, 2026 Clinical Data Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate pharminent May 15, 2026 Clinical Data Regenxbio’s Duchenne gene therapy clears phase 3 hurdle pharminent May 14, 2026
